Daiken Biomedical Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	1,628	1,362	1,190	884.97
Revenue Growth (YoY)	31.96%	14.45%	34.52%	-
Cost of Revenue	575.12	506.17	376.66	271.66
Gross Profit	1,052	856.22	813.76	613.3
Selling, General & Admin	810.19	696.26	601.78	493.5
Research & Development	10.79	10.16	7.82	7.36
Operating Expenses	821.87	707.3	609.61	500.87
Operating Income	230.63	148.92	204.15	112.44
Interest Expense	-2.93	-6	-3.36	-1.18
Interest & Investment Income	30.53	28.43	2.87	0.2
Currency Exchange Gain (Loss)	-40.11	-31.85	-8.39	-1.92
Other Non Operating Income (Expenses)	89.67	0.11	0.08	0.01
Pretax Income	307.78	139.6	195.35	109.54
Income Tax Expense	60.83	33.02	35	19.36
Net Income	246.95	106.58	160.35	90.17
Net Income to Common	246.95	106.58	160.35	90.17
Net Income Growth	116.87%	-33.53%	77.83%	-
Shares Outstanding (Basic)	60	44	22	16
Shares Outstanding (Diluted)	60	44	22	16
Shares Change (YoY)	139.65%	95.20%	44.34%	-
EPS (Basic)	4.11	2.43	7.16	5.80
EPS (Diluted)	4.11	2.43	7.13	5.79
EPS Growth	-9.44%	-65.93%	23.14%	-
Free Cash Flow	214.45	50.5	105.21	41.58
Free Cash Flow Per Share	3.57	1.15	4.68	2.67
Dividend Per Share	8.619	4.033	4.860	4.170
Dividend Growth	290.02%	-17.02%	16.55%	-
Gross Margin	64.66%	62.85%	68.36%	69.30%
Operating Margin	14.17%	10.93%	17.15%	12.71%
Profit Margin	15.17%	7.82%	13.47%	10.19%
Free Cash Flow Margin	13.18%	3.71%	8.84%	4.70%
EBITDA	236.62	153.13	205.07	112.54
EBITDA Margin	14.54%	11.24%	17.23%	12.72%
D&A For EBITDA	6	4.21	0.92	0.1
EBIT	230.63	148.92	204.15	112.44
EBIT Margin	14.17%	10.93%	17.15%	12.71%
Effective Tax Rate	19.76%	23.65%	17.91%	17.68%
Advertising Expenses	-	380.08	383.45	329.81

Source: S&P Global Market Intelligence. Standard template. Financial Sources.